Svenska
MENUMENU

Press releases

October 8th, 2018 13:41

R Immunovia announces strategic focus centered on IMMray™ blood-based biomarker signatures for rheumatoid arthritis within autoimmunity

LUND, Sweden ― Encouraged by the promising discovery study results previously reported, Immunovia´s prime focus in autoimmunity testing will be to develop IMMray™ blood-based biomarker signatures for the management of rheumatoid arthritis.

Immunovia, PR RA Strategy

October 4th, 2018 13:52

Immunovia PanFAM-1 clinical trial now available on ClinicalTrials.gov, the largest clinical trials database in the world

LUND, SWEDEN ― Immunovia has developed a blood based biomarker signature for early detection of pancreatic cancer called IMMray™ PanCan-d. To validate IMMray™ PanCan-d, Immunovia started PanFAM-1 (https://immunovia.com/immray-pancan-d/prospective-studies-and-next-step/panfam-1/), the largest ever multicenter clinical trial for early detection of pancreatic cancer in familial/hereditary high risk group, in collaboration with major pancreatic cancer centers from Europe and US. To provide patients, their families, health care professionals and the public with the information about this clinical trial, Immunovia registered PanFAM-1 study to ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03693378?term=PANFAM&rank=1) which is a web-based registry of clinical trials. It is run by the United States National Library of Medicine at the National Institutes of Health, and is the largest clinical trials database, currently holding registrations from over 230,000 trials from 204 countries in the world.

Immunovia, PR PanFAM-1 on ClinicalTrials.gov

September 28th, 2018 12:41

Invitation to conference call regarding Immunovia’s autoimmune diseases strategy on October 8, 2018

Immunovia invites to a teleconference (in English) for investors, analysts and media on October 8, 2018 at 3:00 – 4:00 p.m CET.

Press release Telephone conference RA strategy

September 28th, 2018 08:30

R Increase in share capital and number of shares in Immunovia

The share capital and number of shares in Immunovia AB (publ) has changed due to share warrants being exercised in the company.

Immunovia, PR new number of shares

August 24th, 2018 08:30

R Immunovia Interim report, January-June 2018

“On 3 April, trading in Immunovia’s shares started on NASDAQ Stockholm’s main market, where we are listed in the Mid Cap segment. During the second quarter we also completed a directed share issue worth around SEK 324 million to reputable institutions in Sweden and internationally.

Very exciting results have been achieved in two major application areas, lung cancer and rheumatoid arthritis, which show that the general usability of the IMMray™ platform opens up great opportunities for Immunovia.

During the spring and summer we completed a lung cancer study with very good results. This was our first collaboration with a global, top-ten pharmaceutical business and the aim was to assess the technical performance of the IMMray™ platform within lung cancer.

In the autoimmune field we have made significant progress within rheumatoid arthritis. In August we published results that mean we will now continue our efforts aimed at developing a product for patients that are difficult to diagnose in this area.

The main focus, as usual, was on IMMray™ PanCan-d. Work has proceeded according to plan in the second quarter. In August, however, new data emerged showing that the sample-collection procedure, which will be applicable commercially and for our final validation studies, affects our product’s algorithms. We have therefore decided that a necessary stage is to optimize IMMray™ PanCan-d to safeguard the quality of the test results prior to release. This will delay the start of sales to the latter part of 2019.”

Release

August 23rd, 2018 09:35

Invitation to presentation of Immunovia´s interim report January-June 2018 and comments to the previously published autoimmunity study results

Lund (Sweden) - Immunovia will publish the company’s interim report for the period January-June 2018 on Friday, August 24, at 08:30 a.m. CET.

Immunovia telephone conference Q2 2018

August 22nd, 2018 14:23

R Breakthrough in autoimmune testing – IMMrayTM based novel biomarker signature identifies patients with anti-CCP negative rheumatoid arthritis

LUND, Sweden ― Immunovia today announced that a new study confirms that the IMMray™ blood test successfully addresses one of the major challenges in autoimmune testing. The present study, performed in collaboration with Linköping University, showed that IMMray™ technology can identify patients with rheumatoid arthritis (RA), despite testing negative with antibodies against cyclic citrullinated peptides (CCP). Currently, this important group of patients – representing 25-30% of all RA cases – is missed using the present gold standard assay to analyze IgG-class anti-CCP.

Press release Immunovia RA 180822 ENG

August 16th, 2018 17:34

R Retrospective study results for IMMray™ PanCan-d conclude Immunovia needs to do further optimizations to meet the expected performance

Immunovia AB (publ) (“Immunovia”) finalized today a retrospective study performed as part of the preparation for the certification and accreditation of the company’s commercial version of their IMMrayTM PanCan-d assay for early detection of pancreatic cancer. Due to variations in different biobank blood sampling processes, Immunovia needs to do further optimizations to the test algorithms to meet the expected performance for its commercial version of the test. The further optimization work will delay the initiation of the sales of the IMMrayTM PanCan-d until later part of 2019 and in aggregate render an extraordinary cost of less than SEK 5 million. 

Press release Immunovia IMMray PanCan-d optimization_ENG

August 15th, 2018 08:30

Journal of Clinical Oncology publishes that IMMray™ PanCan-d serum biomarker test detects early pancreatic cancer with 96% accuracy

LUND, SWEDEN ― Immunovia AB announced today that the prestigious Journal of Clinical Oncology (JCO) publishes the results of the major retrospective clinical validation study performed by Scandinavian and US researchers, showing that the IMMray™ PanCan-d serum biomarker microarray detects early pancreatic cancer with 96% accuracy.

Press release Immunovia JCO 180815 ENG

August 9th, 2018 11:52

Invitation to Immunovia’s telephone conference on Thursday, the 9th of August, 2018 at 15:00 (CET)

Due to today's announcement of the non-small cell lung cancer (NSCLC) collaborative study with a major global pharma company, Immunovia invites to a telephone conference today on August 9, at 15:00 (CET). The presentation will be held in English. After a short presentation by CEO Mats Grahn, you will have an opportunity to ask questions. Please dial in a few minutes before the presentation begins.

PR Immunoviateleconference ENG

August 9th, 2018 08:30

Immunovia`s blood-based IMMray™ biomarker array provides highly accurate diagnosis of non-small cell lung cancer in a new collaborative study

LUND, SWEDEN ― Immunovia AB announced today that in a new collaborative study with a major global pharma company, Immunovia ́s innovative blood-based testing platform, IMMray™ could differentiate healthy controls from non-small cell lung cancer (NSCLC) samples with a 95 % accuracy. Accounting for nearly 14% of all new cancers, NSCLC is one of the top three cancer types by incidence and number one by mortality.

Press release Immunovia NSCLC ENG

August 3rd, 2018 16:56

Karolinska Institutet participates in Immunovia’s PanFAM-1 prospective  clinical study for early detection of pancreatic cancer using blood-based test

Prospects rise for world’s first national screening program.

Press release Immunovia Karolinska PanFAM-1

June 29th, 2018 08:00

R Change in number of shares and votes in Immunovia AB (publ)

The number of shares in Immunovia AB (publ) has changed due to the issue of 2,162,794 shares resolved by the Board in June.

Change in number of shares and votes in Immunovia AB (publ)

June 8th, 2018 08:30

R Immunovia has completed a directed share issue of approximately SEK 324 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

Immunovia AB (publ) (“Immunovia” or the “Company”) today announces that the Company has successfully completed a directed share issue which will provide the Company with a gross proceed of approximately SEK 324 million.

Press release Immunovia has completed directed share issue

June 7th, 2018 17:31

R Immunovia announces its intent to carry out a directed share issue

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL

Immunovia AB (publ) (“Immunovia” or the “Company”) today announces its intention to execute a directed share issue to Swedish and international qualified and/or institutional investors (the “Share Issue”). The contemplated Share Issue will be carried out under the authorization received from the annual general meeting on May 3, 2018 and may entail an issue of a maximum number of shares corresponding to a maximum of 20 percent of the number of shares in the Company as of the day of this announcement, i.e. 3,463,611 shares.

Press release Immunovia Share issue

May 22nd, 2018 15:59

Linköping University Hospital second Swedish site in largest ever prospective multicenter clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer.

Press Release Immunovia Linköping PanFAM-1

May 4th, 2018 13:30

Spanish major private hospital joins world’s largest study of familiar risk for pancreatic cancer

PanFAM-1 is the largest ever prospective multicenter study for early detection of pancreatic cancer in one of the main risk groups – families with a history of the disease. The Clínica Universidad de Navarra (CUN) is the latest center to join others across North America and Europe in the trial which uses Immunovia’s innovative IMMrayTM PanCan-d, blood based test as its key tool. If successful it is estimated that survival rates could be improved from 5-8% to 50%.

Release

May 3rd, 2018 18:38

R Immunovia—report from AGM

The Annual General Meeting (AGM) of Immunovia AB (publ), corporate identity number 556730-4299 was held at Gamla Gästmatsalen in Medicon Village, Scheelevägen 2, Lund, Sweden on 3 May 2018. A summary of the Meeting’s resolutions follows:

Release

April 27th, 2018 08:00

R Immunovia Interim report, January-March 2018

“In the first quarter we reached a very important milestone for the company. Almost two years after the listing of Immunovia on Nasdaq First North, we received approval from Nasdaq to begin trading on their main market.

We have also worked intensively towards our next milestone, which is to start sales by the end of 2018.

The company has a target of achieving turnover of SEK 250-300 million by 2021 … and total turnover of SEK 800-1,000 by 2023.”

Extract from comments to the interim report by CEO Mats Grahn.

Release

April 25th, 2018 17:45

Invitation to presentation of Immunovia´s interim report January-March 2018 on April 27, 2018

Lund (Sweden) - Immunovia will publish the company’s interim report for the period January-March 2018 on Friday, April 27, at 08:00 a.m. CET.

Immunovia telephone conference Q1 2018

April 12th, 2018 08:00

NYU School of Medicine joins PanFAM-1 prospective study for the early detection of pancreatic cancer in familiar risk groups

Using Immunovia’s innovative IMMrayTM PanCan-d, blood based test as its key tool, PanFAM-1 is the largest ever prospective multicenter study for early detection of pancreatic cancer in one of the main risk groups – families with a history of the disease. NYU School of Medicine is the latest center of excellence to join others across North America and Europe working to validate IMMrayTM PanCan-d.

Release

April 3rd, 2018 08:47

R Kallelse till Årsstämma i Immunovia AB

Styrelsen i Immunovia AB (publ), org nr 556730-4299, kallar härmed till årsstämma torsdagen den 3 maj 2018, kl. 16.00 i Gamla Gästmatsalen, Inspira, Medicon Village, Scheelevägen 2, Lund.

Release

March 26th, 2018 14:19

Immunovia published prospectus in connection with the change of listing venue to Nasdaq Stockholm

LUND, Sweden ― Earlier today, Nasdaq Stockholm’s listing committee approved Immunovia AB’s (publ) (“Immunovia” or the “Company”) application for admission to trading of the Company’s shares on the regulated marked Nasdaq Stockholm. The prospectus that has been prepared in connection with the change of listing venue has today been approved and registered by the Swedish Financial Supervisory Authority and published on Immunovia’s website, www.immunovia.com.

Release

March 26th, 2018 09:28

Immunovia has been approved for listing on Nasdaq Stockholm

LUND ― Nasdaq Stockholm’s listing committee has approved Immunovia AB’s (publ) (“Immunovia” or the “Company”) application for admission to trading of the Company’s shares on the regulated marked Nasdaq Stockholm. The approval is subject to customary conditions, including the approval and registration of a prospectus by the Swedish Financial Supervisory Authority.

Release

March 23rd, 2018 13:08

Immunovia launches new website today

LUND, Sweden - Immunovia is inviting visitors to explore its newly redesigned website -www.immunovia.com. The new website has been created to provide visitors detailed, extensive and up to date information about Immunovia´s core technology, IMMray™ and its first test for early diagnosis of pancreatic cancer, IMMray™ PanCan-d.

PR Immunovia launches new website

March 20th, 2018 14:50

R Immunovia publishes the annual report for the financial year 2017

LUND - Immunovia has today published the annual report for 2017 in Swedish. It is available on Immunovia's website.

Press release Immunovia ÅR

March 12th, 2018 08:30

R Immunovia announces financial targets

LUND, Sweden - The Board of Directors of Immunovia AB (publ) (“Immunovia” or the “Company”) has today adopted financial targets due to the fact the Company, as previously announced, will begin sales during second half of 2018. The financial targets show that the Company’s goal is to reach SEK 250-300 million in turnover in 2021 based on “self-pay”-sales and a turnover of SEK 800-1,000 million in 2023 including self-pay and reimbursements in Europe and the US.

Press release financial targets

February 16th, 2018 14:32

Spanish center Santiago de Compostela joins the largest ever prospective study into familial risk of developing pancreatic cancer

International validation through collaboration with leading cancer centers in Europe and US is a key part of Immunovia’s development and commercialization strategy for its portfolio of IMMrayTM tests. Therefore, the company has initiated PanFAM-1, the largest ever prospective multicenter study for early detection of pancreatic cancer using IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer. Today Immunovia is pleased to announce that Spanish pancreatic cancer Santiago de Compostela has joined in this endeavor.

Release

February 15th, 2018 08:00

R Immunovia Full Year report, January-December 2017

“The fourth quarter of 2017 marked an important inflection point for Immunovia in many aspects. We ended our final year of purely pre-commercial activity, and have now started what is planned as our first business year that will lead to the start of sales in the second half of 2018.”

“During 2018 we expect to reach our target of starting commercial sales of IMMray™  PanCan –dby providing the test to customers, both private individuals and health organizations, so-calledself-pay customers.”

“The internal work aimed at preparing the company for a listing on Nasdaq Stockholm’s main market was completed in 2017. We have submitted our application and we are expecting to receive a decision in the first quarter of 2018.” Mats Grahn, CEO, Immunovia.

Release

February 12th, 2018 16:54

Invitation to presentation of Immunovia´s Full Year Report 2017 on February 15, 2018

Lund (Sweden) - Immunovia will publish the company’s Full Year Report 2017 for the period January – December 2017 on Thursday, February 15, at 08:00 a.m. CET.

Invitation to presentation of Immunovia Q4 2017

February 8th, 2018 07:10

Massachusetts General Hospital joins PanFAM-1 prospective study for the early detection of pancreatic cancer in familiar risk groups

Forming collaborations and establishing a presence in the USA is central to Immunovia’s reimbursement strategy and market introduction. The continued expansion of PanFAM-1 into the largest ever prospective multicenter study for early detection of pancreatic cancer is another vital step towards these goals.  The participation of the prestigious MassGen will strengthen the study, which is designed to validate IMMrayTM PanCan-d, Immunovia´s blood-based test for early detection of pancreatic cancer

Release

January 11th, 2018 14:27

Immunovia accelerates pancreas cancer study of new onset diabetics by adding Denmark’s Diabetes Center for Strategic Research-DD2

LUND, Sweden ― Immunovia AB (publ) (“Immunovia”) has today signed a letter of intent for collaboration with the Danish Center for Strategic Research into Type 2 Diabetes (DD2). The intention is that the DD2 Center will be part of the groundbreaking PanDIA-1 prospective study into new onset Type 2 diabetics over 50 and their associated risk of developing pancreatic cancer. 

Release

December 22nd, 2017 14:32

R Immunovia expands multicenter clinical study for early detection of pancreatic cancer through collaboration with the renowned University of Pittsburgh

The collaboration with leading pancreas cancer centers in USA is a cornerstone of Immunovias reimbursement strategy and market introduction. The present expansion of PanFAM-1, the largest ever prospective multicenter study for early detection of pancreas cancer is another important step towards these goals.  The study is designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer

Release

December 20th, 2017 14:54

R Sahlgrenska University Hospital first Swedish site in the largest ever prospective clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood based test for early detection of pancreatic cancer 

Release

December 18th, 2017 15:02

Invitation to Immunovia’s telephone conference on Wednesday, the 20th of December, 2017 at 15:00 (CET)

Immunovia invites you to a telephone conference regarding the initiation of PanDIA-1, the world’s largest prospective study of the new onset diabetes (NOD) risk group for pancreatic cancer. The telephone conference will take place 15:00 (CET) the 20th of December, 2017.

Release

December 18th, 2017 08:30

R Immunovia initiates the world’s largest study of new onset diabetic patients in a prospective pancreas cancer study supported by SWElife

Sample collection providing access of up to 6 000 new onset diabetic patients is based on a collaboration including Sweden´s two major universities Lund and Uppsala, Lund University Diabetic Center, as well as Skåne and Uppsala healthcare regions.

Immunovia SWElife 20171218

November 30th, 2017 17:21

The Swedish Royal Technology Mission 2017 and His Majesty King Carl XVI Gustaf of Sweden visited Immunovia yesterday

LUND, Sweden ― The Swedish Royal Technology Mission 2017 and His Majesty King Carl XVI Gustaf of Sweden as the Guest of Honor visited yesterday, the 29th of November, 2017, CREATE Health Cancer Center and four of the most innovative companies at Medicon Village. The delegation of prominent political and industry leaders included Skånes County Governor Anneli Hulthen as well as IVA President Prof Tuula Teeri. Leif Johansson, the Presiding Officer of the Royal Institute of Technology was leading the delegation.

The Swedish Royal Technology Mission 2017 and His Majesty King Carl XVI Gustaf of Sweden visited Immunovia yesterday

November 16th, 2017 08:30

World Pancreatic Cancer Day is today: If pancreatic cancer is found early, it saves lives

LUND, Sweden ―Today on World Pancreatic Cancer Day, pancreatic cancer remains to show one of the lowest survival rates among all major cancers. In nearly every country, pancreatic cancer is the only cancer with a single-digit five-year survival rate (2-9 percent). Every day, more than 1,000 people worldwide will be diagnosed with pancreatic cancer, and an estimated 985 will die from the disease. It is estimated that by 2020, 418,000 new cases will be diagnosed globally.

Release

November 13th, 2017 09:02

Immunovia will hold a Q3 report telephone conference on Monday Nov 13th

Mats Grahn, CEO, Immunovia, will hold a Q3 report telephone conference on Monday Nov 13th at 16:00 CET.

Release

November 10th, 2017 08:30

R Immunovia Interim report, January-September 2017

“The important prospective studies for the pancreas test within the diabetes group (“PANDIA-1”) and the early symptoms group (“PANSYM-1”) have in discussions with clinical partners made progress for both PANDIA-1 and PANSYM-1. At the end of October, collection of blood samples began from patients with early symptoms at University College London Hospital. This was a very significant milestone for PANSYM-1. The retrospective, diabetes risk-group study based on the biobank from Region Skåne is also now under way.”

Release

November 7th, 2017 14:05

R Immunovia AB (Publ) nomination committee appointed for AGM 2018

According to the instruction that was adopted at the Immunovia AB (Publ) AGM April 25 2017, the nomination committee should consist of three members.

Release

November 2nd, 2017 08:43

R University College London Hospital starts the collection of blood samples to evaluate IMMray™ PanCan-d in symptomatic patients

University College London Hospital will assess Immunovia’s IMMray™ PanCan-d in 360 patients with symptoms suggestive of early pancreatic cancer

Release

October 31st, 2017 17:00

R Increase in share capital and number of shares in Immunovia

The share capital and number of shares in Immunovia AB (publ) has changed due to share warrants being exercised in the company.

·          The share capital has increased from SEK 840,902.95 to SEK 865,902.95.
·          The number of shares has increased by 514,000 to 17,318,059 shares.
·          The dilution amounts to 3.1%.

Release

October 30th, 2017 16:41

R Immunovia receives SEK4.9 Million grant from Swelife Accelerator Innovation Program

The grant supports completion of the development studies of IMMray™ PanCan-d, the first blood-based test for early stage pancreatic cancer to enable increased possibility of successful surgical intervention.

Release

October 23rd, 2017 10:34

R Immunovia signs major autoimmune biomarker discovery collaboration with Linköping University

Aim to develop next generation of autoimmune diseases diagnostics based on IMMray™ antibody array platform.

Release

October 2nd, 2017 11:25

Immunovia AB on track regarding application for listing on Nasdaq Stockholm’s main market

As previously announced, the company’s preparations of internal processes to meet the requirements on Nasdaq Stockholm’s main market were expected to be completed in September for initiation of the formal listing process. This goal has been achieved and Nasdaq reviews and formal processes will now follow as planned with the goal to list the company on Nasdaq Stockholm’s main market.

Release

September 26th, 2017 18:00

R Management and employees of Immunovia subscribe for new shares by exercising warrants

Release

September 7th, 2017 15:51

R Immunovia announces collaboration with Lund University Diabetes Centre for the early detection of pancreatic cancer in diabetes risk group

LUND, Sweden ― Immunovia AB is delighted to announce a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population. 

PR Immunovia LUDC retro diabetes ENG

August 23rd, 2017 08:30

R Immunovia Interim report, January-June 2017

“During Q2 we announced that we are establishing our American office in Boston. The head office for the US includes our own reference laboratory that complements our earlier collaboration with Knight Diagnostic Laboratories and gives us delivery capacity in both the east and west of the United States.”

“Another highlight for Immunovia during the quarter was the excellent results from the study of differentiation of Rheumatoid Arthritis (RA), Sjögren’s Syndrome and Systemic Vasculitis. These results complement the ones from the earlier differential study that we presented for SLE in Q1. They further confirm that our IMMrayTMplatform is generally applicable for many unsolved clinical problems within both cancer and autoimmunity while specifically strengthening our possibilities in the autoimmunity field.”

“During the quarter we announced that, together with Knight Cancer Institute at OHSU, we received a research grant from PanCAN, a patient advocacy group, to support a retroactive analysis of American patients who developed pancreatic cancer after being diagnosed with diabetes.”

Release

August 18th, 2017 08:00

Immunovia invites to a conference call on August 23, 2017

Immunovia invites to a conference call in connection with reporting the half-year results 2017. The conference call will take place at 16:00 on August 23 and the result is expected to be published at 8:30 AM the same day.

Release

July 17th, 2017 08:43

R Leading expert on pancreatic cancer, Professor Stephen Pereira at University College London, joins Immunovia’s Scientific Advisory Board

LUND, Sweden ― Immunovia announced today that Professor Stephen Pereira, one of the globally leading experts in the diagnosis of early symptoms of pancreatic cancer and a multidisciplinary diagnostic center champion has been appointed to the company’s Scientific Advisory Board. Currently, Pereira is Professor of Hepatology & Gastroenterology at UCL, University College London, and an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and The Royal Free Hospital.  

Release

June 30th, 2017 08:30

R Immunovia together with Oregon Health and Science University awarded one of the Pancreatic Cancer Action Network 2017 Research Grants

LUND, Sweden ― On the 28th of June, it was announced that Pancreatic Cancer Action Network (PanCAN), the largest patient advocacy group in USA, in partnership with generous donors, awarded Prof. Brett Sheppard and Prof. Rosalie Sears from Oregon Health and Science University one of the Research grants for 2017 of a value of $ 250.000.

Release

June 28th, 2017 08:30

R Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston

LUND, Sweden ― Immunovia today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized.  This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilitating commercialization, covering marketing, sales and customer support.

Release

June 21st, 2017 08:30

R Immunovia’s IMMray™ presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy

LUND, Sweden - Immunovia today announced that they have completed the analysis of the three other autoimmune diseases included in the previously reported large, retrospective autoimmune disease study, performed in collaboration with Department of Immuntechnology, Lund University. The study included 315 blood samples and covered main autoimmune indications such as, Systemic Lupus Erythematosus Rheumatoid Arthritis (RA), Sjögren’s Syndrome, Systemic Vasculitis and healthy controls. For SLE, two sets of differential diagnosis data were previously reported March 7 2017.

Release

June 16th, 2017 08:30

R Immunovia AB announces timetable for listing on Nasdaq Stockholm's main market

LUND, Sweden - The Board of Directors of Immunovia AB today announces timetable for the application for listing of the company's shares on Nasdaq Stockholm's main market. Immunova's shares are currently traded on Nasdaq First North under the ticker IMMNOV.

Release

June 13th, 2017 15:00

R Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan

LUND, Sweden ― Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer.  Japanese Patent No. JP 6115801, is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test. 

Release

April 25th, 2017 17:45

R Immunovia Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299, har hållits den 25 april 2017 i Gamla Gästmatsalen på Medicon Village, Scheelevägen 2, Lund. Nedan följer en sammanfattning av de beslut som fattades.

Release

April 20th, 2017 08:30

R Immunovia Interim report, January-March 2017

Release

April 19th, 2017 11:06

Immunovia inbjuder till telefonkonferens den 20 april 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av första kvartalet 2017. Telefonkonferensen äger rum kl. 16:00 den 20 april och resultatet beräknas publiceras kl. 8:30 samma dag.

Release

March 24th, 2017 08:30

R IMMUNOVIA AB KALLAR TILL ÅRSSTÄMMA OCH PUBLICERAR ÅRSREDOVISNING FÖR RÄKENSKAPSÅRET 2016

Release

March 7th, 2017 08:30

R Final data from major Swedish study confirms that IMMray™ biomarker microarray differentiates SLE from other autoimmune diseases with 96% accuracy

LUND, Sweden: Immunovia today announced that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray™ blood-based biomarker signatures in differentiating SLE from three other main autoimmune diseases: rheumatoid arthritis, Sjögren disease and vasculitis. There is a clear clinical need for such a test since more than 50% of SLE patients are being initially misdiagnosed, mainly due to ambiguous laboratory test results.

Release

February 22nd, 2017 08:40

R Immunovia tillkännager genomförd blocktransaktion i bolagets aktier

Release

February 15th, 2017 08:00

R Immunovia Financial Statement 2016

Release

February 14th, 2017 10:00

R Immunovia inbjuder till telefonkonferens den 15 februari 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2016. Telefonkonferensen äger rum kl. 16.00 den 15 februari och resultatet beräknas
publiceras kl. 08.00 samma dag.

Release

February 13th, 2017 11:14

R Immunovia presenterar vid Vator Securities Unicorn Summit

Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 7 mars 2017 på IVA i Stockholm, med start klockan 11.30.

Release

January 16th, 2017 11:45

R University of Michigan Pancreatic Cancer Center new partner in Immunovia’s global PANFAM-1 prospective validation study

LUND, Sweden, and Ann Arbor, USA ― Immunovia AB is pleased to announce that the University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating in the PANFAM-I prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals.

Release

January 13th, 2017 14:45

Immunovia bjuder in till telefonkonferens tisdag 17/1 kl 16:00

Med anledning av gårdagens offentliggörande av studieresultaten där Immunovia kan påvisa att IMMray™ biomarkörsignatur kan särskilja Systemic Lupus Erythematosus (SLE) med 90 procents träffsäkerhet från andra autoimmuna sjukdomar, inbjuder Immunovia till telefonkonferens på tisdag 17 januari, kl 16:00.

Release

January 12th, 2017 18:35

R Immunovia announces first data exceeding 90% accuracy in distinguishing systemic lupus erythematosus (SLE) from other autoimmune diseases in new study

LUND, Sweden ― Immunovia today announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray™ biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an average accuracy exceeding 90%. These results are extremely encouraging because the symptoms of SLE mimic other rheumatic, autoimmune diseases leading to more than 50% of the patients being initially misdiagnosed, mainly due to ambiguous laboratory test results. It is estimated that as many as 5 million people suffer from SLE and it may take up to 3 years from symptoms appearing to diagnosis and treatment.

Immunovia press release SLE

December 22nd, 2016 11:30

Immunovia Shareholder Newsletter Q4 2016

Dear Immunovia Shareholders,

With the end of the year approaching and many of you looking forward to a well-deserved Christmas and New Year celebration, we at Immunovia would also like you to join us in celebrating an unprecedented year which we are sure you would agree has more than surpassed expectations. In this newsletter, we would like to give you a summary of the milestones and highlights of a highly successful 2016 and the outlook for what is shaping up already to be an equally productive 2017. In particular 2016 was an exciting year as we started implementing Immunovia’s commercialization plan focussing on the goal of achieving reimbursement and national guideline status.

Release

December 20th, 2016 08:00

R Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.

Release

December 9th, 2016 11:28

R Summary from the extraordinary general meeting of Immunovia

Extraordinary General Meeting of Immunovia AB (publ), 556730-4299, has been held in the confernce room ”Gamla Gästmatsalen”, House 302, Medicon Village, Scheelevägen 2, 223 63 Lund, December 9, 2016. Below is a summary of the resolutions of the extraordinary general meeting.

Release

December 9th, 2016 10:40

R Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Immunovia and NCI (National Cancer Institute), has in a memorandum of understanding agreed to collaborate towards a common goal of cancer biomarker development and validation, in particular regarding early detection of pancreatic cancer in the risk group of new onset diabetes over 50 years.

Release

December 9th, 2016 08:00

R Immunovia announces collaboration with the renowned Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid

LUND, Sweden, and MADRID, Spain ― Immunovia AB is delighted to announce the addition of the leading Spanish research centre Ramon y Cajal Institute for Health Research (IRYCIS) to a global network of leading sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe that offer high risk pancreatic cancer screening programs. 

Release

November 18th, 2016 16:33

R Immunovia awarded 2016 Stars of Innovation Prize

Leading-edge healthcare diagnostics company making major progress in Europe.

Release

November 16th, 2016 08:30

R KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)

Release

November 15th, 2016 15:00

WORLD PANCREATIC CANCER DAY, LUND SWEDEN, November 17, 2016 - It's About Time

Every day, more than 900 people around the world die from pancreatic cancer. Only 6 percent of the patients diagnosed with pancreatic cancer survive 5 years. According to a recent global survey, more than 60 percent of people know “almost nothing” about pancreatic cancer.

Release

October 19th, 2016 17:00

R Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee.

Release

October 13th, 2016 13:30

R Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016

Stars of Innovation nomination recognizes stellar performance since IPO

Release

October 7th, 2016 12:00

R Immunovia: Insiders transfer subscription rights free of charge

LUND, Sweden ― Within the framework of the ongoing rights issue at Immunovia AB (publ) ("the company ") Carl Borrebaeck and Christer Wingren, Chairman of the Board and Chief Technical Officer respectively at the company, have, on request from professional investors and in consultation with the company's financial advisor Vator Securities, transferred all subscription rights received in the rights issue to named investors.

Press release PDF

September 26th, 2016 13:30

R Immunovia publishes prospectus regarding preferential rights issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia publishes prospectus regarding preferential rights issue

Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”).

Publication of prospectus
Immunovia’s prospectus, prepared in connection with the Rights Issue, has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus has today been published and is also available on the company’s web page http://immunovia.com/investors/ and the Company’s head office.

Press release PDF

September 15th, 2016 08:30

R The board of directors of Immunovia resolves on a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

The board of directors of Immunovia resolves on a directed and preferential right issue

Press release Immunovia resolves on a directed and preferential right issue

September 14th, 2016 17:30

R Immunovia intends to launch a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.

Immunovia intends to launch a directed and preferential right issue

Summary
Immunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares.

Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK 30 million with preferential right for the Company’s existing shareholders.

Press release PDF

September 5th, 2016 08:30

R Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer

The best chance to influence the survival of non-hereditary pancreatic cancer patients is to focus on early detection of cases in people aged over 50 who receive their first diagnosis of diabetes. There is now clear unanimity on this, and both public authorities and health institutes focused on the link between diabetes and pancreatic cancer are initiating research programmes on a large scale across several countries in order to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group.

Press release PDF

August 24th, 2016 08:30

R Immunovia Half-year report 2016

Press release PDF

August 17th, 2016 08:30

R Immunovia invitation to a teleconference on 24 August 2016

Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same day

Press release PDF

August 16th, 2016 08:30

R Immunovia announces intention to apply for listing on Nasdaq Stockholm's Main Market

The Board of Immunovia AB (publ) ("Immunovia" or the "Company") today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm's Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker.

Press release PDF

July 15th, 2016 10:00

R Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board

Extensive expertise in clinical tumor management and tumor biomarkers, will help accelerate pancreatic cancer diagnostic program

Press release PDF

July 5th, 2016 08:45

R World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology and Diagnostics at the University and Hospital Trust of Verona in Italy.

Press release PDF

June 23rd, 2016 14:00

R Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF.

Press release PDF

May 31st, 2016 09:14

R Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299 har hållits lokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund den 30 maj 2016. Nedan följer en sammanfattning av de beslut som fattades.

Press release PDF

May 30th, 2016 10:30

R Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer

Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancer

Press release PDF

May 30th, 2016 08:00

R 96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort

Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer  

Press release PDF

May 18th, 2016 15:45

Inbjudan till Immunovia Informationsmöte i Stockholm den 1 juni kl 17.30 med VD MatsGrahn och Styrelseordförande Carl Borrebaeck

Aktieägare som inte har möjlighet att deltaga på Immunovias bolagsstämma den 30 maj i Lund samt övriga intresserade hälsas välkomna till ett informationsmöte där VD Mats Grahn och Styrelseordförande Carl Borrebaeck informerar om bolagets utveckling under 2015 och därefter.

May 9th, 2016 13:00

IMMUNOVIA JOINS MORE THAN 40 GLOBAL PANCREATIC CANCER ORGANIZATIONS AT INAGURAL MEETING

World Pancreatic Cancer Coalition Aims to Raise Unprecedented Awareness for a Disease with the Lowest Survival Rate of Any Major Cancer.  

PR Immunovia World Pancreatic Cancer Coalition

April 26th, 2016 10:30

R Immunovia kallar till årsstämma 2016

Styrelsen i Immunovia AB (publ) har kallat  till årsstämma den 30 maj 2016. Stämman kommer att hållas kl 16.00 i samlingslokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund.

PDF Press release

April 8th, 2016 11:35

R Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer.

Press release PDF

April 1st, 2016 13:42

NOTE about Immunovia and IMMray™ technology information on newswires and social media

March 9th, 2016 12:20

R Immunovia partners with leading healthcare consultingservices firm

Immunovia partners with leading healthcare consulting services firm to support market access of pancreatic cancer test in Germany
*
Immunovia announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray™ PanCan-d in Germany

PDF Press release

March 8th, 2016 10:05

Immunovia launches Swedish website

February 29th, 2016 15:55

R Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLE

Press release PDF

February 24th, 2016 14:00

R Immunovia Year-end report 2015

Year-end report 2015

February 10th, 2016 08:00

R Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures

Immunovia initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for SLE also known as “lupus”. 

Release

February 9th, 2016 09:27

R Immunovia announces collaboration with Mount Sinai Health System to validate early detection blood test for pancreatic cancer

LUND, Sweden, and NEW YORK, USA ― Immunovia AB is pleased to announce that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting second half of 2016.

Release

January 19th, 2016 10:07

R Immunovia and the University of Liverpool enter into a collaboration in a prospective clinical study

LUND, Sweden, and Liverpool, UK ― Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study. In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical Research Unit, based at the Royal Liverpool University Hospital. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half of 2016.

Release

December 18th, 2015 13:45

R White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

LUND, Sweden ― In this White Paper, Immunovia summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates from 4-6% to 50-60%.

Release

December 3rd, 2015 11:15

R IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples

Largest ever study for diagnosing pancreatic cancer paves way for early intervention to significantly improve survival rates.

Release

December 2nd, 2015 16:08

R Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Trading in Immunovia AB’s shares (IMMNOV) commenced yesterday on Nasdaq First North in Stockholm. At closing the share price had surged 60 percent compared to the introduction price. The interest among investors was high. The trading turnover was SEK 28.5 million during the day, thus setting a new record among comparable First North listings during 2015.

November 26th, 2015 14:25

Immunovia approved for trading on Nasdaq First North as of December 1st, 2015

Immunovia AB (publ) has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. Immunovia is a Swedish research company that has developed a new method for using a blood test to diagnose pancreatic cancer. With Immunovia’s test, diagnosis can be made earlier which substantially enhances the possibilities to treat the cancer. A new share issue of SEK 60 million before issue costs have been carried out before introduction on First North.

Release

October 5th, 2015 14:00

Immunovia, OHSU collaborating on early detection test for pancreatic cancer

LUND, Sweden, and PORTLAND, Oregon ― Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.

Press release: Immunovia, OHSU collaborating on early detection test for pancreatic cancer

Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports